• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

大阪都市大学医院抗真菌药物管理的现状与挑战。

Status and Challenge of Antifungal Stewardship at the Osaka Metropolitan University Hospital.

机构信息

Department of Infection Control Science, Graduate School of Medicine, Osaka Metropolitan University.

Department of Infection Control and Prevention, Osaka Metropolitan University Hospital.

出版信息

Med Mycol J. 2024;65(2):33-38. doi: 10.3314/mmj.24.003.

DOI:10.3314/mmj.24.003
PMID:38825528
Abstract

Antifungal stewardship (AFS), compared with antimicrobial stewardship (AS), requires more advanced knowledge, skills, and multidisciplinary collaboration in its implementation. Therefore, fewer facilities are performing AFS compared with AS. At our hospital, we started AS and AFS in 2014. Our AFS programs include the following: i) interventions for patients with yeast-positive blood cultures, ii) introduction of a conditional antifungal notification system, and iii) commencement of AS team rounds. AFS for filamentous fungi includes bronchoscopy and microbial identification, including genetic and drug susceptibility testing. These AFS activities have improved several processes and outcome measures. However, our AFS team has faced several problems owing to the impact of COVID-19. This review introduces the practice of AFS, which we initiated at our hospital in 2014, and presents the current problems.

摘要

抗真菌药物管理(AFS)与抗菌药物管理(ASM)相比,在实施过程中需要更先进的知识、技能和多学科协作。因此,与 ASM 相比,实施 AFS 的医疗机构较少。在我们医院,我们于 2014 年开始实施 ASM 和 AFS。我们的 AFS 计划包括:i)对酵母菌血培养阳性患者进行干预,ii)引入条件性抗真菌药物通知系统,以及 iii)启动 ASM 团队查房。丝状真菌的 AFS 包括支气管镜检查和微生物鉴定,包括基因和药敏试验。这些 AFS 活动改善了多个流程和结果指标。然而,由于 COVID-19 的影响,我们的 AFS 团队面临了一些问题。本综述介绍了我们 2014 年在医院开展的 AFS 实践,并提出了当前存在的问题。

相似文献

1
Status and Challenge of Antifungal Stewardship at the Osaka Metropolitan University Hospital.大阪都市大学医院抗真菌药物管理的现状与挑战。
Med Mycol J. 2024;65(2):33-38. doi: 10.3314/mmj.24.003.
2
Global onychomycosis management and the challenges of antifungal stewardship.全球甲癣管理及抗真菌药物管理面临的挑战
J Dermatolog Treat. 2025 Dec;36(1):2526073. doi: 10.1080/09546634.2025.2526073. Epub 2025 Jul 6.
3
Measures implemented in the school setting to contain the COVID-19 pandemic.学校为控制 COVID-19 疫情而采取的措施。
Cochrane Database Syst Rev. 2022 Jan 17;1(1):CD015029. doi: 10.1002/14651858.CD015029.
4
Antifungal stewardship in Australian hospitals: defining the scope and future targets.澳大利亚医院的抗真菌管理:界定范围与未来目标
Intern Med J. 2025 Feb;55(2):223-232. doi: 10.1111/imj.16571. Epub 2024 Dec 1.
5
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.在基层医疗机构或医院门诊环境中,如果患者出现以下症状和体征,可判断其是否患有 COVID-19。
Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3.
6
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
7
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状Meta分析。
Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3.
8
Convalescent plasma for people with COVID-19: a living systematic review.COVID-19 患者恢复期血浆治疗:一项实时系统评价。
Cochrane Database Syst Rev. 2023 Feb 1;2(2):CD013600. doi: 10.1002/14651858.CD013600.pub5.
9
Physical interventions to interrupt or reduce the spread of respiratory viruses.物理干预措施以阻断或减少呼吸道病毒的传播。
Cochrane Database Syst Rev. 2023 Jan 30;1(1):CD006207. doi: 10.1002/14651858.CD006207.pub6.
10
Convalescent plasma for people with COVID-19: a living systematic review.COVID-19 患者恢复期血浆治疗:一项实时系统评价。
Cochrane Database Syst Rev. 2023 May 10;5(5):CD013600. doi: 10.1002/14651858.CD013600.pub6.